Boston University
Investigating cellular dynamics of regulatory T cells in drug-hypersensitivity reactions
Abstract
dc:description.abstractBackground: Delayed-type drug-hypersensitivity reactions (dtDHRs) are rare, immune- mediated reactions that rapidly progress following the exposure to a prescribed drug. Within 24-72 hours, cutaneous symptoms emerge and carry a high rate of morbidity and mortality for affected patients. Because of the nature of these diseases, it reinforces the importance of developing a deeper understanding of how these diseases develop, and how researchers and physicians should treat and care for affected patients. The most common form of dtDHRs, is morbilliform drug eruptions (MDEs), but severe cutaneous adverse reactions (SCARs), such as Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS), can develop as the disease progresses, prompting immediate intervention. With dtDHRs being T cell-mediated reactions, the investigation into the function of T cells, called regulatory T cells (Tregs), can reveal mechanistically how these reactions develop. Our research focused on the proposed expansion of cytotoxic CD8+ T cells, helper CD4+ T cells, and their subsets throughout the severity of diseases. Through the analysis of blood samples from enrolled patients, and proposed mouse models in the laboratory, our research has progressed to provide insight into these immune-mediated diseases. Objectives: The overarching aim in the Divito Lab (Harvard University, School of Medicine, Boston, MA) is to develop an ex-vivo test to identify culprit drugs causing dtDHRs. More specifically, our team is investigating how Tregs within culture samples will impact downstream assays, as a result of their suppressive nature. Through this understanding of baseline cellular dynamics of Tregs, our team utilized flow cytometry and separation techniques to identify the percentage of Tregs within patient samples, displaying the immune cells present within varying degrees of dtDHRs. Finally, pilot studies utilizing HLA-B*57:01 and HLA-B*15:02 mouse models will allow the lab to further develop an adequate mouse model that can parallel human conditions. Methods: Following patient recruitment in accordance with the approved Institutional Review Board (IRB), skin biopsies and blood samples were obtained from prospective patients. Using peripheral blood mononuclear cell (PBMC) isolation techniques, live cells were counted and analyzed through flow cytometry (Cytek Aurora; Cytek Biosciences, Fremont, CA). In addition, HLA-B*57:01 phenotyping and HLA-B*15:02 genotyping experiments were conducted to identify positive and negative mouse pups for future development of an adequate diseased mouse model. Results: Through flow cytometry analysis, various immune cell populations and their presence within patient samples were identified. The main markers studied were CD3+ T cells, cytotoxic CD8+ T cells, helper CD4+ T cells, Tregs, and APCs among healthy controls and MDE, DRESS, and SJS/TEN patients. Analysis revealed not only a significant increase in Tregs in DRESS patients in comparison with healthy controls, but also a suspected expansion of CD8+ T cells in patients. With this preliminary data, further experimentation and exploration will be conducted with larger cohorts. Conclusion: Through our research and experimentation, the baseline activity of Tregs amongst severity of disease has been revealed. Understanding how functioning Tregs play a role in dampening disease has shown to be beneficial in unveiling the underlying mechanisms leading to the development of dtDHRs. With this preliminary knowledge, our team hopes to apply the findings to develop a Treg-depleted mouse model that can further display Treg activity in affected patients. With larger patient cohort sizes and extensive mouse experimentation, we hope to further progress our knowledge in dtDHRs and implement preventative measures and practices within hospital settings to aid affected patients and further limit the development of dtDHRs.
Degree
thesis:*- Name thesis:degree_name
- Master of Science
- Level thesis:degree_level
- masters
- Discipline thesis:degree_discipline
- Medical Sciences
- Grantor
- Boston University
- Year dc:date.issued
- 2026
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Youssef, Maya Rewan
- Advisors dc:contributor.advisor
-
- Divito, Sherrie J
- Spencer, Jean L
Subjects
dc:subject × 3Rights
- Language dc:language.iso
- en_US
Identifiers
dc:identifier.*- Handle dc:identifier.uri
- https://hdl.handle.net/2144/53789